China's Hengrui Pharma Receives Clinical Trial Approval for Bladder Cancer Combination Therapy... Triple Combo of SHR-2005, IL-15 Fusion Protein, and Adebrelicept
China's Hengrui Pharmaceuticals (恒瑞医药·600276.SH) is set to develop a new anticancer combination therapy for bladder cancer. A clinical trial combining its self-developed innovative anticancer drug, an interleukin-15 (IL-15) fusion protein, and an immune checkpoint inhibitor has received approval fro

China's Hengrui Pharmaceuticals (恒瑞医药·600276.SH) is set to develop a new anticancer combination therapy for bladder cancer. A clinical trial combining its self-developed innovative anticancer drug, an interleukin-15 (IL-15) fusion protein, and an immune checkpoint inhibitor has received approval from China's drug regulatory authorities.
■ Background of Approval... SHR-2005 and SHR-1501 as Base Combination, with Adebrelicept and BCG as Optional Additions
Hengrui announced on the 26th through a Shanghai Stock Exchange disclosure that its three subsidiaries have received clinical trial approval notices from China's National Medical Products Administration (NMPA) for SHR-2005 injection, SHR-1501 for injection, and adebrelicept injection.
The approved clinical trial targets a bladder cancer treatment that basically combines SHR-2005 and SHR-1501, with the optional addition of adebrelicept injection and BCG. The related clinical trial application was submitted on May 7, and the NMPA determined that it met drug registration requirements and allowed the trial to proceed. Hengrui plans to commence the clinical trial shortly.
■ SHR-2005... An Innovative Anticancer Drug with No Same-Class Drugs Domestically or Abroad
SHR-2005 is an innovative anticancer drug independently developed by Hengrui, being developed for the treatment of bladder cancer. The company stated that no drugs of the same class have currently been launched either in China or overseas.
■ SHR-1501... An IL-15 Fusion Protein That Promotes Immune Cell Proliferation
SHR-1501 is an IL-15 fusion protein independently developed by Hengrui. IL-15 is a substance involved in the proliferation and activation of immune cells, and SHR-1501 has the characteristic of inducing antitumor effects by promoting the proliferation of T cells, B cells, and natural killer (NK) cells in the body. Hengrui leveraged these properties to include SHR-1501 in the bladder cancer combination therapy.
Overseas, Anktiva, a drug in the same class, has received marketing approval in the United States. In contrast, no drug targeting the same target has yet been approved in China. According to EvaluatePharma data cited by Hengrui, Anktiva's global sales in 2025 amounted to approximately US$113 million.
■ Adebrelicept... An Anti-PD-L1 Immunotherapy Drug Approved for Two Lung Cancer Indications
Adebrelicept, included in the combination therapy, is a humanized anti-PD-L1 monoclonal antibody independently developed by Hengrui. The drug works by binding to PD-L1 and blocking the PD-1/PD-L1 signaling pathway, thereby restoring the immune system's antitumor activity.
Adebrelicept has already received approval for two indications in China. The first is first-line treatment of extensive-stage small cell lung cancer in combination with carboplatin and etoposide, and the second is perioperative treatment for adults with resectable non-small cell lung cancer with no confirmed specific genetic mutations. The latter involves neoadjuvant therapy in combination with platinum-based chemotherapy followed by adjuvant monotherapy after surgery. However, the newly approved bladder cancer combination therapy is a clinical trial separate from the previously approved lung cancer indications.
The market for immunotherapy drugs targeting PD-L1 already includes multiple products. Notably, Tecentriq, Bavencio, and Imfinzi have received marketing approval in the United States, with Tecentriq and Imfinzi also approved in China. Hengrui stated that the combined 2025 global sales of these three drugs amount to approximately US$11.054 billion.
■ Cumulative R&D Costs for the Three Drugs Total 1.5564 Billion Yuan
The cumulative research and development costs for the drugs included in this bladder cancer combination therapy were also disclosed. Approximately 56.6 million yuan has been invested in SHR-2005 and approximately 129.5 million yuan in SHR-1501, while adebrelicept accounts for the largest amount at approximately 1.3703 billion yuan. The combined cumulative R&D costs for the three drugs reach approximately 1.5564 billion yuan.
However, these figures represent cumulative costs invested in projects related to each drug and do not reflect amounts spent solely on this bladder cancer clinical trial. All figures are unaudited.
■ Review and Final Approval Remain Before Commercialization... "Uncertainties Exist"
Hengrui explained that even after this clinical trial approval, additional procedures are required before actual drug production and sales. Under China's pharmaceutical regulations, clinical trials must be conducted, followed by NMPA review and final approval, before commercialization is possible. The company also noted that drug development involves multiple stages—clinical trials, approval review, and production—and uncertainties may arise during the process. Hengrui plans to pursue the related R&D while disclosing subsequent progress.
With this approval, Hengrui can now conduct clinical trials for a bladder cancer combination therapy utilizing its self-developed anticancer drug SHR-2005, SHR-1501 involved in immune cell proliferation, and the previously approved immunotherapy drug adebrelicept. How the safety and efficacy of this combination therapy will manifest in future clinical trials remains a key challenge for its research and development.
[This article is intended to provide information for investment reference purposes and does not recommend the purchase or sale of any specific stock. Content may vary depending on market conditions. Investment decisions and any resulting responsibility rest with the investor. AI assistance was used in part.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] US October Retail Sales Rise 6.8% Year-on-Year, 0.2% Month-on-Month... Economic Indicators in Focus After CPI and PPI](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F627311%2Fa2376e0512277714%2Fvariants%2Fhero.webp&w=1920&q=75)
![[Breaking] Cyberattack via Optimizely Exposes 178 Global Organizations... CNN, BBC, HSBC, and Ledger Also Affected](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F627874%2Ffc472b72a2596aa1%2Fvariants%2Fhero.webp&w=1920&q=75)

